Agenus Inc. — Q1 2015 Form 10-Q
Business context and period. Immunotherapy developer focused on antibody/checkpoint-modulator programs, heat shock protein vaccines, and QS-21 vaccine adjuvant. This summary covers the three months ended March 31, 2015; financial statements are unaudited. Most programs were in preclinical or clinical development, and Agenus had no established source of recurring product sales.
Financial performance and liquidity
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | $3.95 million | $0.72 million |
| Research and development expense | $9.22 million | $4.47 million |
| General and administrative expense | $5.49 million | $5.16 million |
| Operating loss | $18.29 million | $9.82 million |
| Net loss | $18.74 million; $0.28 per common share | $0.36 million; $0.01 per common share |
| Net cash from (used in) operations | $3.30 million | $(10.12) million |
| Cash and cash equivalents at period-end | $79.30 million | $25.71 million at Dec. 31, 2014 |
Revenue was primarily license and collaboration revenue, including Incyte agreement revenue. The filing reports no clear gross-margin figure; the company’s development-stage business is not presented with a conventional product gross margin. Q1 2015 operating cash flow was supported substantially by Incyte upfront consideration and deferred revenue, and management cautioned that the quarter’s positive operating cash flow is not indicative of future results.
Total assets were $117.32 million and stockholders’ equity was $46.26 million at March 31, 2015. Current liabilities were $21.00 million. Debt principal outstanding was $14.4 million, including $14.0 million of 8% subordinated notes due February 2018; the company made the final approximately $278,000 payment on its Silicon Valley Bank loan in April. Accumulated deficit was $710.0 million. No conventional liquidity or profitability guidance beyond management’s cash-runway estimate was provided.
Material changes versus the prior comparable period
- Revenue increased to $3.95 million from $0.72 million, reflecting collaboration activity, including Incyte. Of the Incyte upfront payment, approximately $1.3 million was recognized as revenue in the quarter; approximately $23.7 million remained deferred at March 31.
- R&D expense more than doubled, primarily due to increased checkpoint-modulator program costs and higher headcount. Management reported 2015 checkpoint-modulator program expense of $7.61 million.
- Net loss rose substantially. Q1 2014 included $9.82 million of non-operating income, primarily from a change in the fair value of the contingent royalty obligation; Q1 2015 instead included a $7.54 million contingent purchase-price fair-value expense and a $154,000 debt-extinguishment loss.
- Cash and cash equivalents rose from $25.71 million to $79.30 million. Cash inflows included $35 million from Incyte’s stock purchase, a $25 million Incyte upfront payment, and $9 million of new subordinated debt. The company also paid a $20 million acquisition-related milestone, with the cash-flow statement reporting $8.18 million of contingent purchase-price payments during the quarter.
- Incyte purchased approximately 7.76 million shares for $35 million, and Agenus issued warrants for 1.4 million shares with the new notes. Shares outstanding were 70.84 million at March 31 and 71.49 million on April 27.
Outlook, commentary, and risks
- Management said available working capital was expected to fund requirements through the first half of 2016. It expected continued losses and said additional funding could be needed; options included partnerships, asset sales, debt, or equity issuance. A $150 million shelf registration and an at-the-market facility covering up to 10 million shares were available.
- Agenus planned to file two INDs in 2015 for GITR- and CTLA-4-targeting antibodies and anticipated first checkpoint-modulator clinical trials in 2016. Under the Incyte alliance, GITR and OX40 costs and profits are shared 50:50; Incyte reimburses LAG-3 and TIM-3 development costs, with potential milestones and royalties. Future payments depend on development and commercial success.
- Management was exploring a partner or other funding to advance the Phase 3-ready Prophage GBM vaccine. QS-21-containing vaccine launches were anticipated by the company in the 2016–2017 timeframe, dependent on licensees’ clinical, regulatory, manufacturing, and commercial progress.
- Liquidity is exposed to ongoing R&D spending, uncertain clinical and regulatory outcomes, dependence on collaborators and licensees, and the possibility that additional financing may not be available on acceptable terms. The filing notes that prolonged losses or inability to raise capital could threaten continued operations.
- Other material risks include Incyte’s ability to perform or continue the collaboration, manufacturing and trial-enrollment challenges, competitive and intellectual-property risks, and foreign-currency exposure. Agenus did not use derivatives or hedging for currency or interest-rate exposures.
- After quarter-end, Agenus acquired Celexion antibody-discovery assets for $1 million cash, 574,140 shares, and additional scheduled consideration. The filing also disclosed the April 13, 2015 death of a key investigator supporting Prophage-sponsored studies, which could delay or affect those programs.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. The filing does not provide quantified full-year financial guidance.
Investor verification points
- Confirm the composition and expected duration of the stated cash runway, especially given management’s warning that Q1 operating cash flow depended on one-time collaboration receipts.
- Track the timing, costs, and results of the planned 2015 IND filings and 2016 clinical-trial starts, as well as the allocation of costs under the Incyte agreement.
- Verify cash payments, remaining obligations, and fair-value assumptions for the 4-Antibody contingent milestone and the Celexion acquisition consideration.
- Monitor whether QS-21 licensees advance candidates toward approval and whether Prophage programs secure funding, enrollment, and investigator support.
- Assess future financing needs, potential dilution from registered shares, options and warrants, and the terms and servicing of the 8% subordinated notes.